JP2008543890A5 - - Google Patents

Download PDF

Info

Publication number
JP2008543890A5
JP2008543890A5 JP2008517321A JP2008517321A JP2008543890A5 JP 2008543890 A5 JP2008543890 A5 JP 2008543890A5 JP 2008517321 A JP2008517321 A JP 2008517321A JP 2008517321 A JP2008517321 A JP 2008517321A JP 2008543890 A5 JP2008543890 A5 JP 2008543890A5
Authority
JP
Japan
Prior art keywords
vaccine
pharmaceutical composition
composition
immunogenic
mycobacterium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008517321A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008543890A (ja
JP5219808B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/DK2006/000356 external-priority patent/WO2006136162A2/en
Publication of JP2008543890A publication Critical patent/JP2008543890A/ja
Publication of JP2008543890A5 publication Critical patent/JP2008543890A5/ja
Application granted granted Critical
Publication of JP5219808B2 publication Critical patent/JP5219808B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008517321A 2005-06-23 2006-06-20 改良された結核ワクチン Expired - Fee Related JP5219808B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200500924 2005-06-23
DKPA200500924 2005-06-23
DKPA200501393 2005-10-05
DKPA200501393 2005-10-05
PCT/DK2006/000356 WO2006136162A2 (en) 2005-06-23 2006-06-20 Tuberculosis vaccines comprising antigens expressed during the latent infection phase

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013001657A Division JP2013121959A (ja) 2005-06-23 2013-01-09 改良された結核ワクチン

Publications (3)

Publication Number Publication Date
JP2008543890A JP2008543890A (ja) 2008-12-04
JP2008543890A5 true JP2008543890A5 (enExample) 2009-12-24
JP5219808B2 JP5219808B2 (ja) 2013-06-26

Family

ID=37134239

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008517321A Expired - Fee Related JP5219808B2 (ja) 2005-06-23 2006-06-20 改良された結核ワクチン
JP2013001657A Pending JP2013121959A (ja) 2005-06-23 2013-01-09 改良された結核ワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013001657A Pending JP2013121959A (ja) 2005-06-23 2013-01-09 改良された結核ワクチン

Country Status (12)

Country Link
US (4) US7968105B2 (enExample)
EP (4) EP2380589A3 (enExample)
JP (2) JP5219808B2 (enExample)
KR (2) KR101035053B1 (enExample)
CN (1) CN102836425B (enExample)
AU (1) AU2006261445B2 (enExample)
BR (1) BRPI0612833A2 (enExample)
CA (2) CA2612900C (enExample)
ES (1) ES2647070T3 (enExample)
IL (3) IL188222A (enExample)
MX (1) MX2007016165A (enExample)
WO (1) WO2006136162A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19529931C1 (de) 1995-08-02 1997-04-03 Mannesmann Ag Plattenkokille zur Erzeugung von Strängen aus Stahl
EP1523331B1 (en) * 2002-07-13 2013-02-27 Statens Serum Institut Therapeutic tb vaccine
MX2009010800A (es) * 2007-04-04 2010-01-29 Infectious Disease Res Inst Id Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos.
HRP20150177T1 (hr) * 2007-04-12 2015-04-10 Mico Bio, Inc. Cjepivo protiv tuberkuloze i postupak upotrebe tog cjepiva
WO2009003474A1 (en) * 2007-06-29 2009-01-08 Statens Serum Institut The use of monomycolyl glycerol (mmg) as an adjuvant
CN101969976A (zh) * 2008-01-11 2011-02-09 美国政府健康与人类服务部秘书处 针对分枝杆菌的多肽疫苗和接种策略
US20100015171A1 (en) * 2008-07-15 2010-01-21 Statens Serum Institute Vaccines comprising tb 10.4
UA107330C2 (uk) 2008-07-25 2014-12-25 Глаксосмітклайн Байолоджікалз С.А. Туберкульозний білок rv3616c та його застосування
US9603919B2 (en) * 2009-03-31 2017-03-28 Japan As Represented By The Director-General Of National Institute Of Infectious Diseases Method for prophylaxis of influenza using vaccine for intranasal administration
CN102413837B (zh) 2009-04-24 2015-11-25 国立血清研究所 预防再激活的结核病tb疫苗
WO2011013097A2 (en) * 2009-07-29 2011-02-03 Bernd Helmut Adam Rehm Polymer particles and uses thereof
US10357555B2 (en) * 2012-07-10 2019-07-23 Transgene Sa Mycobacterial antigen vaccine
RU2520078C1 (ru) * 2013-04-25 2014-06-20 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации (ФГБУ "НИИЭМ им. Н.Ф. Гамалеи" Минздрава России) СПОСОБ ПОЛУЧЕНИЯ ИММУНОГЕННОЙ КОМПОЗИЦИИ НА ОСНОВЕ ГИБРИДНОГО БЕЛКА Ag85A-DBD И ДЕКСТРАНА, РЕКОМБИНАНТНАЯ ПЛАЗМИДА pAg85A-DBD, ШТАММ Escherichia coli [pREP4, pAg85A-DBD], ХИМЕРНЫЙ БЕЛОК Ag85A-DBD
RU2520737C1 (ru) * 2013-04-25 2014-06-27 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт эпидемиологии и микробиологии имени почётного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации (ФГБУ "НИИЭМ им. Н.Ф. Гамалеи" Минздрава России) СПОСОБ ПОЛУЧЕНИЯ ИММУНОГЕННОЙ КОМПОЗИЦИИ НА ОСНОВЕ ГИБРИДНОГО БЕЛКА pESAT6-DBD И ДЕКСТРАНА, РЕКОМБИНАНТНАЯ ПЛАЗМИДА pESAT6-DBD, ШТАММ Escherichia coli, ХИМЕРНЫЙ БЕЛОК ESAT6-DBD И ИХ ПРИМЕНЕНИЕ
RU2539026C1 (ru) * 2013-06-11 2015-01-10 Федеральное государственное бюджетное учреждение "Центральный научно-исследовательский институт туберкулеза" Российской академии медицинских наук РЕКОМБИНАНТНАЯ ПЛАЗМИДА pESAT6-CFP10-DBD, РЕКОМБИНАНТНЫЙ ШТАММ Escherichia coli M15 [pREP4, pESAT6-CFP10-DBD], СПОСОБ ПОЛУЧЕНИЯ, ИММОБИЛИЗАЦИИ, КОНЦЕНТРИРОВАНИЯ И ОЧИСТКИ РЕКОМБИНАНТНОГО БЕЛКА ESAT6-CFP10-DBD НА ДЕКСТРАНЕ, РЕКОМБИНАНТНЫЙ БЕЛОК ESAT6-CFP10-DBD И ИММУНОГЕННАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ БЕЛОК ESAT6-CFP10-DBD
EP3013364B1 (en) 2013-06-25 2022-08-03 International AIDS Vaccine Initiative, Inc. Tuberculosis compositions and methods of using the same
RU2695462C2 (ru) * 2014-01-09 2019-07-23 Трансген Са Гибридизация гетероолигомерных микобактериальных антигенов
WO2017218867A1 (en) * 2016-06-16 2017-12-21 Aeras Tuberculosis compositions and methods of treating or preventing tuberculosis
CN107970444B (zh) * 2016-10-25 2022-03-01 中国人民解放军第三0九医院 复合佐剂及含有该复合佐剂的疫苗
PH12021553146A1 (en) * 2019-06-14 2024-04-22 Statens Seruminstitut Fusion proteins for tuberculosis vaccines
US20250345408A1 (en) * 2020-09-23 2025-11-13 The General Hospital Corporation Bcg vaccinations for prevention of covid-19 and other infectious diseases
KR102709729B1 (ko) * 2020-12-04 2024-09-25 주식회사 제넥신 결핵의 예방 또는 치료용 약학적 조성물
CN115598041B (zh) * 2021-07-07 2025-08-19 中国科学院微生物研究所 结核鉴别诊断细胞因子及其在结核感染风险评估中的应用
KR20240153581A (ko) 2022-02-21 2024-10-23 스태튼스 세룸 인스티튜트 신규한 양이온 어주번트 조성물
CN117531001A (zh) * 2023-11-15 2024-02-09 首都医科大学附属北京胸科医院 结核分枝杆菌毒素抗毒素系统及其相关应用
CN118108815B (zh) * 2024-04-23 2024-07-23 成都康华生物制品股份有限公司 结核分枝杆菌多免疫原抗原、编码其的mRNA、应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1331C (da) 1897-11-15 Hans Daae Militær- og Skilygte.
US4599230A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599231A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4608251A (en) 1984-11-09 1986-08-26 Pitman-Moore, Inc. LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US6641814B1 (en) 1997-04-02 2003-11-04 Statens Serum Institut Nucleic acids fragments and polypeptide fragments derived from M. tuberculosis
EP2045261A1 (en) * 1994-09-20 2009-04-08 Hitachi Chemical Co., Ltd. Chlamydia pneumoniae antigenic polypeptides
ATE339436T1 (de) 1995-06-07 2006-10-15 Sanofi Pasteur Inc Expression von lipoproteinen
US20040018574A1 (en) * 1998-08-25 2004-01-29 Marcel Behr Molecular differences between species of the M. tuberculosis complex
CN1377355A (zh) 1999-09-30 2002-10-30 纽罗杰有限公司 氨基取代的吡唑并[1,5－a]－1,5－嘧啶和吡唑并[1,5－a]－1,3,5－三嗪
WO2001079274A2 (en) 2000-04-19 2001-10-25 Statens Serum Institut Tuberculosis antigens and methods of use thereof
WO2002004018A2 (en) 2000-07-10 2002-01-17 Colorado State University Research Foundation Mid-life vaccine and methods for boosting anti-mycobacterial immunity
US20030180953A1 (en) * 2000-12-29 2003-09-25 Elitra Pharmaceuticals, Inc. Gene disruption methodologies for drug target discovery
US20030119013A1 (en) * 2001-04-23 2003-06-26 Bo Jiang Identification of essential genes of Aspergillus fumigatus and methods of use
EP2196473A1 (en) * 2001-07-04 2010-06-16 Health Protection Agency Mycobacterial antigens expressed during latency
EP1523331B1 (en) * 2002-07-13 2013-02-27 Statens Serum Institut Therapeutic tb vaccine

Similar Documents

Publication Publication Date Title
JP2008543890A5 (enExample)
JP2008539187A5 (enExample)
US11224646B2 (en) Intranasal delivery of a cyclic-di-nucleotide adjuvanted vaccine for tuberculosis
Ingolotti et al. DNA vaccines for targeting bacterial infections
JP2013507907A5 (enExample)
JP2012524733A5 (enExample)
JP2008530245A5 (enExample)
HRP20120331T1 (hr) Postupak sprječavanja ili liječenja infekcije bakterijom m. tuberculosis
US10004793B2 (en) M.tuberculosis vaccines
EP3013364B1 (en) Tuberculosis compositions and methods of using the same
KR20170072366A (ko) 재활성화를 예방하기 위한 결핵 백신
BRPI0905725B1 (pt) vacina e embalagem farmacêutica
JP2015524794A5 (enExample)
CN104736555A (zh) 结核分枝杆菌疫苗
Kaufmann Tuberculosis vaccine development at a divide
CN101745104A (zh) 含有复合佐剂的结核亚单位疫苗
CN106237317A (zh) 由结核分枝杆菌抗原组成的结核疫苗
CN101451145A (zh) 基于t细胞表位的结核基因疫苗及其制备方法和应用
Liang et al. Immunotherapeutic effects of Mycobacterium tuberculosis rv3407 DNA vaccine in mice
Mobed DNA Based vaccines against Mycobacterium tuberculosis: recent progress in vaccine development and delivery system
Avarvand et al. The roles of latency-associated antigens in tuberculosis vaccines
BR112012011395B1 (pt) Uso de uma fonte de l3 e/ou l5 como uma vacina ou como um diagnóstico para uma doença parasítica
Rivas-Santiago et al. Novel approaches to tuberculosis prevention: DNA vaccines
Li et al. Improved humoral immunity against tuberculosis ESAT-6 antigen by chimeric DNA prime and protein boost strategy
EP1833507B1 (en) Compositions for immunizing against mycobacterium